hero image

Biogen Idec Announces March 25 Webcast of Research & Development Day

March 18, 2009 News Release

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ:BIIB) announced today that it will hold its 2009 R&D Day on Wednesday, March 25, 2009 from 1 PM ET to 5 PM ET. Dr. Cecil Pickett, Biogen Idec's President of Research & Development, along with members of the Company's R&D leadership team will provide a detailed review of the Company's pipeline programs.

Media, investors and the general public can access the live event by visiting the "Investor" section of the Biogen Idec web site, investor.biogenidec.com. Audio and slide presentations will be available through the web site. An archived version of the webcast will be available for 30 days following the presentation.

About Biogen Idec

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.



Biogen Idec
Investor Relations
Rob Jacobson, 617-679-2812

March 22, 2023
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS

SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United States CAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Biogen Inc.  (Nasdaq: BIIB) announced today the outcome of the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System

March 17, 2023
Biogen to Participate in the Stifel 2023 CNS Days

Cambridge, MA, - -  Biogen Inc.   (Nasdaq: BIIB) announced today that Priya Singhal, M.D., M.P.H., Head of Development, will participate in the Stifel 2023 CNS Days. The webcast will be live on Tuesday, March 28, 2023, at 9:15 a.m. ET. To access the live webcast, please visit the Investors section